City University

Mellon Foundation Awards More Than $18 Million to Public Colleges and Universities for Race, Ethnic, Gender, and Sexuality Studies

Retrieved on: 
Martedì, Marzo 26, 2024
Knowledge, Minor, Gender, Culture, University of Montana, Ethnic studies, Education, University, Exercise, University of Kansas, Human, Philosophy, KU, AAPI, Metropolitan area, California State University, Commons, Humanities, Indigenous education, City University, Research, History, Faculty, Andrew W. Mellon Foundation, Student, Transgender, CUNY, Long Beach, California, Social change, UHM, Teaching, Nursing

NEW YORK, March 26, 2024 /PRNewswire/ -- The Mellon Foundation announced today that as part of an ongoing commitment to supporting humanities-based learning, the foundation has awarded more than $18 million to 95 public college and university programs—across 66 institutions—that boldly advance the study of race, ethnicity, gender or sexuality through its new 'Affirming Multivocal Humanities' initiative. Funding will support both established and novel curricular programs and co-curricular activities ranging from undergraduate research projects and guest speaker series, microgrants for community organizations and external programs to promote clear understandings of the fields to the public.

Key Points: 
  • As the nation's largest funder of the arts, culture, and humanities, Mellon has long supported the exploration of multivocality within the academic space.
  • Through the Affirming Multivocal Humanities initiative, the foundation further addresses the continuing need for nuanced scholarship on the breadth of the human experience through race, ethnic, gender, and sexuality studies.
  • As part of Affirming Multivocal Humanities, Mellon offered grants of $100,000 to public colleges and universities that awarded at least ten bachelor's degrees in women's/gender and sexuality studies or in any individual US ethnic studies field in 2021.
  • The expansion will focus on programs that link Ethnic Studies concepts to Gender and Sexuality Studies to embed intersectionality into the course content and program frameworks.

STEVEN & ALEXANDRA COHEN FOUNDATION AWARDS $116 MILLION GRANT TO LAGUARDIA COMMUNITY COLLEGE TO CREATE THE COHEN CAREER COLLECTIVE

Retrieved on: 
Mercoledì, Marzo 20, 2024
Organization, Community development, Veteran, Associate, Trustee, City University, Hospitality, Health care, History, City, Telephone directory, Community college, United, LaGuardia Community College, Life, Student, CUNY, ESL, New Yorker, Workforce, Disability, Multimedia, Television, Nursing

LONG ISLAND CITY, N.Y., March 20, 2024 /PRNewswire/ -- The Steven & Alexandra Cohen Foundation, led by philanthropist and New York Mets owner Alex Cohen, has awarded a grant of $116.2 million to LaGuardia Community College in Long Island City, Queens, to create the Cohen Career Collective, a state-of-the-art workforce training center. The 160,000 square-foot facility will ensure economic mobility for New Yorkers while providing skilled workers for local employers.

Key Points: 
  • The Steven & Alexandra Cohen Foundation has awarded a grant of $116.2 million to LaGuardia Community College /CUNY.
  • "We are profoundly grateful for this incredible gift from the Steven & Alexandra Cohen Foundation," said Kenneth Adams, President of LaGuardia Community College.
  • We are proud to create the Cohen Career Collective and are committed to our neighbors here in Queens."
  • We are truly honored that she turned to LaGuardia to bring her vision to life through the creation of the Cohen Career Collective."

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against GrafTech, Instacart, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Sabato, Marzo 9, 2024
Uber, News, Neurobiology of Aging, Form, Apoptosis, IPO, Health, Particulates, Cassava Sciences, City University, P.C, Electrode, ALS, Register, Initiative, Cassava, AMX0035, Journal, Graphite, IBD, Evercore, EAF, Amyotrophy, Environment, DoorDash, Complaint, Safety, Biomarker, Public expenditure, Sustainable development, Amylyx Pharmaceuticals, Science, Prescription, Prospectus, GrafTech, Reuters, Scientific misconduct, BBC World Service, Alzheimer's disease, FDA, Food, Data management, Investor's Business Daily, Government, Patient, Cognition, Defendant, Pharmaceutical industry

The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.

Key Points: 
  • The Company sells and delivers a range of products in the food, alcohol, consumer health, pet care, and ready-made meals categories, in addition to others.
  • The Company offers its services through a mobile application and website, while also providing software-as-a-service solutions to retailers.
  • In addition, the complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding the Company's business, operations, and prospects.
  • For more information on the Amylyx class action go to: https://bespc.com/cases/AMLX

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Cassava Sciences, Inc. of Class Action Lawsuit and Upcoming Deadlines – SAVA

Retrieved on: 
Giovedì, Marzo 7, 2024
Pomerantz, City University, Court, Person, FDA, Prior, News, Data management, Neurobiology of Aging, Complaint, District court, Ext, Initiative, Safety, Cassava, Biomarker, Patient, Cognition, Journal, LLP, Science, Cassava Sciences, Action Replay, Pharmaceutical industry

NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).

Key Points: 
  • NEW YORK, March 07, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Cassava Sciences, Inc. (“Cassava” or the “Company”) (NASDAQ: SAVA).
  • To discuss this action, contact Danielle Peyton at [email protected] or 646-581-9980 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

SHAREHOLDER ACTION REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Retrieved on: 
Giovedì, Marzo 7, 2024
Scientific misconduct, Court, Alzheimer's disease, FDA, News, Advertising, Data management, Neurobiology of Aging, Initiative, Safety, Biomarker, Patient, Cognition, Journal, LLP, Science, Cassava Sciences, City University, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Cassava, Amylyx, Sunnova, and DICK’S Sporting Goods and Encourages Investors to Contact the Firm

Retrieved on: 
Martedì, Marzo 5, 2024
News, Neurobiology of Aging, Commerce, Apoptosis, The Washington Free Beacon, Energy, Sunnova, DOE, Cassava Sciences, State, City University, P.C, House Committee, ALS, Initiative, Cassava, AMX0035, Journal, Electricity, IBD, Evercore, Amyotrophy, Complaint, Safety, NOVA, Biomarker, Amylyx Pharmaceuticals, Outdoor, Science, Prescription, Scientific misconduct, BBC World Service, Alzheimer's disease, DKS, FDA, Food, Data management, Investor's Business Daily, Nature, Letter, Risk, Natural Resources, Patient, Cognition, Defendant, Pharmaceutical industry

The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.

Key Points: 
  • The Company's lead therapeutic drug candidate is PTI-125 (or "simufilam"), a small molecule drug for the proposed treatment of Alzheimer's disease.
  • Then, on August 22, 2023, Dick’s Sporting Goods revealed that profitability for the second quarter of 2023 was significantly lower than previously represented.
  • Dick’s Sporting Goods also lowered its profitability guidance for the rest of fiscal year 2023.
  • For more information on the DICK’S Sporting Goods class action go to: https://bespc.com/cases/DKS

Norton Rose Fulbright welcomes two highly regarded financial services partners in New York

Retrieved on: 
Lunedì, Marzo 4, 2024
Public policy, Law school, Financial services, Lawyer, Columbia Law School, CEA, Chambers and Partners, Record, Growth, CFTC, MBA, Private law, Yale Law School, LLM, University, Sarah Lawrence College, JD, University of Oxford, News, Commodity Futures Trading Commission, Contract management, City University, Commodity Exchange Act, Financial adviser

New York, March 04, 2024 (GLOBE NEWSWIRE) -- Global law firm Norton Rose Fulbright today announced that financial services lawyers Steven Lofchie and Mark Highman have joined the firm as partners in the New York office.

Key Points: 
  • New York, March 04, 2024 (GLOBE NEWSWIRE) -- Global law firm Norton Rose Fulbright today announced that financial services lawyers Steven Lofchie and Mark Highman have joined the firm as partners in the New York office.
  • Regarded as one of the leading financial services practitioners in the US, Lofchie counsels clients on securities laws, the Commodity Exchange Act (CEA) and related bankruptcy issues in his regulatory practice.
  • Clients look to Norton Rose Fulbright to guide them through such challenges, and Steve and Mark further strengthen our multidisciplinary offering to the financial services industry.”
    Vincent Dunn, Norton Rose Fulbright’s New York Co-Partner-in-Charge, commented:
    “Norton Rose Fulbright’s New York office has been serving clients in the financial services sector for more than a century.
  • Norton Rose Fulbright provides a full scope of legal services to the world’s preeminent corporations and financial institutions.

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Cassava

Retrieved on: 
Venerdì, Marzo 1, 2024
Scientific misconduct, Court, Alzheimer's disease, FDA, News, Advertising, Data management, Neurobiology of Aging, Initiative, Safety, Biomarker, Patient, Cognition, Journal, LLP, Science, Cassava Sciences, City University, Pharmaceutical industry

Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.

Key Points: 
  • Faruqi & Faruqi is a leading national securities law firm with offices in New York, Pennsylvania, California and Georgia.
  • The firm has recovered hundreds of millions of dollars for investors since its founding in 1995.
  • Faruqi & Faruqi, LLP also encourages anyone with information regarding Cassava’s conduct to contact the firm, including whistleblowers, former employees, shareholders and others.
  • The law firm responsible for this advertisement is Faruqi & Faruqi, LLP ( www.faruqilaw.com ).

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Boeing, Brooge, Cassava, and Amylyx and Encourages Investors to Contact the Firm

Retrieved on: 
Venerdì, Marzo 1, 2024
Boeing, News, Fraud, Neurobiology of Aging, Apoptosis, Cassava Sciences, MAX, City University, P.C, ALS, Initiative, Cassava, AMX0035, Journal, IBD, Security (finance), Evercore, Amyotrophy, Alaska Airlines, BROG, BIA, Complaint, Safety, Biomarker, Crash, Amylyx Pharmaceuticals, Science, Prescription, Scientific misconduct, BBC World Service, Alzheimer's disease, FDA, Food, Data management, Investor's Business Daily, Gaping, Risk, Patient, Cognition, Defendant, Pharmaceutical industry

Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.

Key Points: 
  • Its Commercial Airplanes Segment is a leading producer of commercial aircraft and offers a family of commercial jetliners including its 737 MAX.
  • Throughout the Class Period, Defendants continued to assure investors that Boeing was laser-focused on safety and quality.
  • These false and misleading statements caused Boeing stock to trade at artificially inflated prices during the Class Period.
  • Also, according to the filed complaint, it took a near disaster to expose this heightened safety risk.

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

Retrieved on: 
Mercoledì, Febbraio 28, 2024
Research, ARIA, FLNA, Drug development, ADAS, Exercise, ADAS-Cog, Private law, Mass spectrometry, Criterion, CDR, Bawskee 3.5, Protein, Intellectual property, Patient, Plasma, Cassava Sciences, PET, MRI, City University, Hyperkinesia, Cerebrospinal fluid, Edema, Cassava, Memory, Insulin, G&A, Tablet, Brain, City, CUNY, SAP, Calendar, Completion, Safety, Clinical, Knowledge, Alzheimer's disease, Magnetic resonance imaging, Blood, FDA, Ageing, Food, Data, Lymphocyte, Medicine, DSMB, Pharmaceutical industry

AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates.

Key Points: 
  • AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates.
  • Net cash used in operations full-year 2023 was $82.0 million, consistent with previous guidance.
  • (This amount is not included in the above cash and cash equivalents at December 31, 2023.)
  • Recent corporate highlights include the following:
    In January 2024, we completed a dividend distribution of common stock warrants to shareholders.